Abstract:Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, Salmonella infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible.Abbreviations: ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related gene; AUTAC: autophagy-targeting chimera; CNS: central nervous system; CQ: chloroquine; GABARAP: gamma-aminobutyric acid type A receptor-associated protein; HCQ: hydroxychloroquine; LYTAC: lysosome targeting chimera; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NDD: neurodegenerative disease; PDAC: pancreatic ductal adenocarcinoma; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PROTAC: proteolysis-targeting chimera; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1.

Current Status of Autophagy Enhancers in Metabolic Disorders and Other Diseases

Targeting autophagy drug discovery: Targets, indications and development trends

Targeting Autophagy in the Management of Obesity and Metabolic Diseases

Autophagic Regulation of Lipid Homeostasis in Cardiometabolic Syndrome

Targeting autophagy in disease: established and new strategies

Autophagy Regulators As Potential Cancer Therapeutic Agents: A Review

Targeting Autophagy to Overcome Human Diseases

Targeting Autophagy in Obesity: from Pathophysiology to Management.

Chemical Autophagy Regulators

Synthetic Activators of Autophagy

Autophagy in major human diseases

Therapeutic regulation of autophagy in hepatic metabolism

Autophagy and inflammation an intricate affair in the management of obesity and metabolic disorders: evidence for novel pharmacological strategies?

Autophagy: A Key Regulator of Homeostasis and Disease: An Overview of Molecular Mechanisms and Modulators

Targeting autophagy with small-molecule activators for potential therapeutic purposes

Role of Autophagy in Inherited Metabolic and Endocrine Myopathies

Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management

Pharmaceutical Agents for Targeting Autophagy and Their Applications in Clinics

Molecular Modulators and Receptors of Selective Autophagy: Disease Implication and Identification Strategies

Autophagy-nutrient sensing pathways in diabetic complications

Targeting selective autophagy and beyond: From underlying mechanisms to potential therapies